Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial-Reference-Cited by-同舟云学术

Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial

Published:2016-09-15 Issue:12 Volume:59 Page:2588-2593
ISSN:0012-186X
Container-title:Diabetologia
language:en
Short-container-title:Diabetologia

Author:

Smits Mark M.,Tonneijck Lennart,Muskiet Marcel H. A.,Kramer Mark H. H.,Pouwels Petra J. W.,Pieters-van den Bos Indra C.,Hoekstra Trynke,Diamant Michaela,van Raalte Daniël H.,Cahen Djuna L.

Funder

Seventh Framework Programme

Novo Nordisk

Publisher

Springer Science and Business Media LLC

Subject

Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00125-016-4100-7.pdf

Reference15 articles.

1. Ahmed A, Wong RJ, Harrison SA (2015) Nonalcoholic fatty liver disease review: diagnosis, treatment, and outcomes. Clin Gastroenterol Hepatol 13:2062–2070

2. Smits MM, van Raalte DH, Tonneijck L et al (2016) GLP-1 based therapies: clinical implications for gastroenterologists. Gut 65:702–711

3. Smits MM, Tonneijck L, Muskiet MHA et al (2015) Cardiovascular, renal and gastrointestinal effects of incretin-based therapies: an acute and 12-week randomised, double-blind, placebo-controlled, mechanistic intervention trial in type 2 diabetes. BMJ Open 5:e009579

4. Kim D, Kim WR, Kim HJ, Therneau TM (2013) Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. Hepatology 57:1357–1365

5. Cuthbertson DJ, Irwin A, Gardner CJ et al (2012) Improved glycaemia correlates with liver fat reduction in obese, type 2 diabetes, patients given glucagon-like peptide-1 (GLP-1) receptor agonists. PLoS One 7:e50117

Cited by 113 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current and experimental pharmacotherapy for the management of non-alcoholic fatty liver disease;Hormones;2024-08-07

2. Review of current and new drugs for the treatment of metabolic-associated fatty liver disease;Hepatology International;2024-06-08

3. Role of lifestyle and glucagon‐like peptide‐1 receptor agonists for weight loss in obesity, type 2 diabetes and steatotic liver diseases;Alimentary Pharmacology & Therapeutics;2024-05-30

4. Incretin-based investigational therapies for the treatment of MASLD/MASH;Diabetes Research and Clinical Practice;2024-05

5. Evolution of characteristics of MASLD with and without diabetes: A meta- analysis of placebo arms;2024-01-30